News stories about CASI Pharmaceuticals (NASDAQ:CASI) have been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. CASI Pharmaceuticals earned a news impact score of 0.06 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.1636105488991 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
CASI has been the topic of several analyst reports. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of CASI Pharmaceuticals in a report on Tuesday, January 16th. Maxim Group set a $4.00 price target on CASI Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, November 14th. Finally, BidaskClub downgraded CASI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday.
Shares of CASI Pharmaceuticals (NASDAQ CASI) traded down $0.01 during midday trading on Friday, hitting $3.84. The stock had a trading volume of 93,398 shares, compared to its average volume of 274,736. CASI Pharmaceuticals has a 1-year low of $0.91 and a 1-year high of $4.84. The company has a market cap of $249.21, a P/E ratio of -32.00 and a beta of 0.71.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.